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Abstract
PTEN-controlled PI3K-AKT-mTOR pathway represents one of the most deregulated signaling pathways in human cancers.
With many small molecule inhibitors that target PI3K-AKT-mTOR pathway being exploited clinically, sensitive and reliable
ways of stratifying patients according to their PTEN functional status and determining treatment outcomes are urgently
needed. Heterogeneous loss of PTEN is commonly associated with human cancers and yet PTEN can also be regulated on
epigenetic, transcriptional or post-translational levels, which makes the use of simple protein or gene expression-based
analyses in determining PTEN status less accurate. In this study, we used network component analysis to identify 20
transcription factors (TFs) whose activities deduced from their target gene expressions were immediately altered upon the
re-expression of PTEN in a PTEN-inducible system. Interestingly, PTEN controls the activities (TFA) rather than the expression
levels of majority of these TFs and these PTEN-controlled TFAs are substantially altered in prostate cancer mouse models.
Importantly, the activities of these TFs can be used to predict PTEN status in human prostate, breast and brain tumor
samples with enhanced reliability when compared to straightforward IHC-based or expression-based analysis. Furthermore,
our analysis indicates that unique sets of PTEN-controlled TFAs significantly contribute to specific tumor types. Together,
our findings reveal that TFAs may be used as ‘‘signatures’’ for predicting PTEN functional status and elucidate the
transcriptional architectures underlying human cancers caused by PTEN loss.
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Introduction
The PTEN (phosphatase and tensin homologue deleted on
chromosome 10) tumor suppressor gene is mutated frequently in
human cancers and cancer predisposition disorders [1,2]. PTEN
status not only pays a role in tumorigenesis, but also a crucial
determinant for efficacy of cancer treatments. It has been shown
that tumors with PTEN deficiency do not respond to Her2
inhibitor [3] or EGFR inhibitor [4] treatments whereas restored
PTEN activity sensitized the tumor cells to these treatments.
Accumulated evidence suggest that PTEN functional deficiency
can result from different mechanisms, including PTEN genomic
deletion, gene mutations, epigenetic silencing (e.g. silencing by
DNA methylation or miRNAs), impaired membrane recruitment
(e.g. loss of interaction with MAGI2) or decreased protein
stability/activity mediated by various post-translational modifica-
tion (e.g. phosphorylation, acetylation, oxidation, ubiquitination)
[5,6]. Therefore, it is rather difficult to determine PTEN
functional status using simple gene expression or immunohisto-
chemistry analysis.
Determination of PTEN functional status can be further
complicated by the intricate signaling pathways that are regulated
by PTEN. Through its lipid phosphatase activity, PTEN regulates
PI3K-AKT-mTOR signaling that are involved in downstream
transcription machineries, such as NF-kB, FOXO, and p53
[7,8,9,10,11]. PI3K-AKT signaling also engages other associated
signaling networks and key factors responsible for cell size, cell
motility, cell cycle, and cell death regulation [12]. Although
regulation of PTEN-PI3K-AKT signaling cascade has been
vigorously exploited, the multi-level controls of PTEN expression
and activity and the complexity of feedback regulatory loops from
PI3K downstream effectors to upstream receptor tyrosine kinase
expression and activities have made determination of PTEN
functional status and response of PTEN deficient tumors towards
PI3K-AKT-mTOR pathway inhibition difficult. For example,
inhibitors targeting PI3K, AKT and mTOR have been tested in
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multiple clinical trials [13]; however, it is recently reported that
AKT inhibitors can induce the expression and phosphorylation of
multiple upstream receptor tyrosine kinases (RTKs) whereas
mTOR inhibitor rapamycin can activate AKT through a negative
feedback mechanism [14]. Thus, the phospho-status of individual
downstream signaling components, such as P-AKT and P-S6K,
may not accurately represent PTEN status nor reflect the ultimate
activation status of the PI3K/AKT signaling pathway.
To decipher functional status of PTEN and PTEN-controlled
signaling network, we first analyzed the transcriptional targets
which are immediately regulated by PTEN expression using global
gene expression profiling in a PTEN inducible system. We further
hypothesized that vast target gene expression changes may be
controlled by a few key transcription factors (TFs), which can be a
more sensitive and accurate ‘‘signature’’ for PTEN status.
However, expression levels of these TFs will not always be
sufficient to reflect their activity since the activity of a transcription
factor (TFA) is controlled by various post-translational modifica-
tions as well as co-activator and co-repressor activities. Previous
works by us and others have shown that TFA can be best inferred
from the transcript levels of its direct target genes, rather than its
mRNA level using Network Component Analysis (NCA)
[15,16,17]. NCA is a model-based decomposition method to
deduce transcription factor activity (TFA) and regulation control
strength (CS) of TFs from target gene expression and information
of TF - gene interactions. The information of TF - gene
interaction, or network connectivity, is constructed by chromatin
immunoprecipitation (ChIP) analysis [18], DamID methylation
profiling [19] or extensive literature search [20].
In this study, we identified 20 TFs whose activities are
immediately altered upon the reexpression of PTEN (see
Figure 1A for our overall strategy) in the Pten null mouse
embryonic fibroblasts (MEFs). We found that the activities of these
PTEN-controlled TFs are significantly altered in prostate cancer
mouse models. Furthermore, the TFAs of these TFs show
enhanced sensitivity and specificity when used to predict PTEN
status in human prostate, breast and brain tumors, as compared to
the gene expression-based analysis.
Results
Identification of transcription factors whose activities are
perturbed by PTEN re-expression
To identify transcription factors whose expressions or activities
are directly regulated by PTEN re-expression, an inducible system
was generated in which PTEN expression can be controlled in a
doxycycline-dependent manner in the Pten null PtenDloxp/Dloxp cells
[21]. PTEN protein level was significantly induced one day after
20 mg/ml doxycycline treatment and approached WT level on
day 2 (Figure 1B; PtenL/L is a Pten WT line and isogenic to
PtenDloxp/Dloxp). Consistent to our previous study, re-expression of
PTEN was able to suppress the gene expression of p90MDM2
isoform without significant change in p76MDM2 isoform as
previously reported (Figure S1A) [21].
Next we analyzed global gene expression alterations immediate
following PTEN re-expression by comparing gene expression levels
1 and 2 days after doxycycline (20 mg/mL) treatment with those
before the treatment (Figure 1C; 1-0 and 2-0) and identified 352
genes whose expressions are changed by 2-fold within 2 days upon
PTEN re-expression. Among these PTEN-induced genes, 136
(38.6%) are up regulated and 216 (61.4%) are down regulated by
PTEN re-expression. Table S1 lists these genes along with their
fold changes after inducing PTEN expression.
We reasoned that the PTEN-inducible genes must be regulated
by the key transcription factors whose activities are controlled by
PTEN. Therefore, we investigated PTEN immediately controlled
TFs via network component analysis (NCA) in which the activities
of TFs (TFAs) are deduced based on expression of their target
genes. Different from conventional gene expression analysis, which
focuses on statistically significant changes of individual genes,
NCA deduces TFAs based on the concordant variations of all,
rather than individual target genes, and that does not require the
analyzed gene expressions to be statistically significant [15]. We
recently developed a new NCA complementary algorithm [16]
that allows analysis of mammalian datasets with limited number of
data points for re-constructing a complicated network with
multiple TFs. Specifically, this trimming algorithm removes the
false positive interactions between TFs and their target genes,
detected via high throughput ChIP-chip analysis, and enables the
key target genes of the TFs of interest to be revealed [16].
We used NCA and the trimming algorithm to construct the
transcription network, based on 70 known TFs and their
controlled 782 target genes [20]. Heatmaps in Figure 1C shows
that 20/70 TFs whose activities (TFAs) are immediately altered by
PTEN re-expression (Figure 1C, right; p,0.05, 2-tail z-test).
Interestingly, only Egr1 and c-Jun show .2-fold changes in their
gene expression levels [22] and NF-kB, c-Myc, Relb, Smad1/7
show 1.5–2.0-fold of changes. These data imply that PTEN
expression may influence the activities of these transcription
factors without significantly changing their expression levels. Of
note, several TFs, such as NF-kB and Hif1a, have been described
as PTEN pathway-regulated TFs by previous reports [23,24].
Unfortunately, Foxo, which is also known to be regulated by
PTEN controlled AKT activity, is not included in this analysis
since its target gene expression values are not available. We refer
these 20 TFs as PTEN-controlled TFs whose activities depend on
PTEN expression status.
PTEN re-expression down-regulates transcription
activities of c-MYC and LEF1
To validate the PTEN-controlled TFs identified in PTEN
inducible MEF cells, we employed another PTEN-inducible
system, the PTEN null human prostate cancer cell line PC3
[6,25]. By using human cell line, we are able to link PTEN-
controlled TFs in mouse model to human cancers. Similar to our
observation in the inducible-PtenDloxp/Dloxp MEFs, PTEN protein
expression is significantly induced after 1 and 2 days of
doxycycline treatment in the inducible-PTEN PC3 cells
(Figure 2A). Using qPCR analysis, we found that the expression
levels of c-MYC and LEF1 after PTEN re-expression in PC3 cells
also echoed those from the MEF-derived data: c-MYC gene
expression is down-regulated (p,0.05) while LEF1 expression level
remained constant (Figure 1C and 2B). We also measured the total
protein level of c-MYC and phosphorylated to total protein ratios
of STAT6 and c-JUN and found no substantial changes in c-MYC
and STAT6 after PTEN re-expression (Figure S1B). In contrast,
the ratio of phospho-c-JUN to total c-JUN is reduced by more
than 2-fold after PTEN re-expression, consistent with our previous
study [26].
The MEF system results predict that transcription activity of c-
MYC would be down regulated by PTEN re-expression in the PC3
system. To validate this, we examined the association between c-
MYC and the promoters of its target genes using chromatin
immunoprecipitation (ChIP) analysis. c-MYC target genes BCAT1,
CDK4, EIF4E, and SHMNT1 were selected because (1) their
proximal promoter regions contain c-MYC consensus binding
sequence (CACGTG), which is conserved between human and
PTEN Controlled Transcription Factor Activities
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mouse; and (2) the control strengths by c-MYC were highly
significant based on NCA analysis (Figure 1C). We found that
PTEN re-expression significantly decreases the association of c-
MYC to the promoter of its target genes (Figure 2C top panel),
and that in turn reduces expressions of these c-MYC target genes
(Figure 2C bottom bar graph). Since PTEN re-expression does not
change the total c-MYC protein level, PTEN must modulate c-
MYC transcription factor activity by either regulating the half-life
of c-MYC or the activities of its binding partners. Similarly, PTEN
re-expression also decreases the association of LEF1 to the
promoter of its target gene WISP1, and that leads to concurrent
reduction of its gene expression (Figure 2D). These results suggest
that transcription activities of both c-MYC and LEF1 are
perturbed by PTEN expression. Furthermore, our data show that
in addition to transcriptional activity, PTEN induction also reduces
c-MYC gene expression, suggesting PTEN-mediated suppression of
c-MYC activity might be partially contributed by its decreased
expression. However, PTEN appears to impact solely on LEF1
activity without altering mRNA expression of the transcription
factor itself.
The activities of PTEN-controlled TFs are substantially
altered in murine prostate cancer models in vivo
PTEN plays a critical role in human and murine prostate
tumorigenesis [1,27,28]. To determine whether TFAs deducted
from PTEN-inducible MEF reflect PTEN functional status in vivo,
we examined the TFAs, based on the gene expression datasets we
have in hand, of three well-established murine prostate cancer
models, i.e. the Pten null [29], the mAKT1 [24], and the hi-c-Myc
[30] models (Figure 3A), and then categorized the TFs into
Figure 1. PTEN re-expression regulates transcription factor expression and activity in PTEN-inducible PtenDloxp/Dloxp MEFs. (A)
Schematic illustration of rationale and approach used in this study. To identify PTEN-controlled TFs, their activities (TFAs) in PTEN inducible system
were first derived from expression of their target genes by NCA. The perturbed TFs were then examined further in mouse models and human cancers.
(B) Immunoblot showing PTEN expression levels at 0, 1, and 2 days after treatment with the indicated concentration of Doxycycline in PtenDloxp/Dloxp
MEFs. Isogenic WT cells (PtenL/L) were used as a positive control. (C) Heatmaps showing the changes of expression and activity (TFA) of transcription
factors in fold and log10 transformed p-value of the z-test, respectively, caused by PTEN re-expression for 1 day (1/0) or 2 days (2/0).
doi:10.1371/journal.pone.0031053.g001
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subgroups according to alterations of their activities in these mouse
models (Figure 3B). Figure S2 illustrates the TFA profiles in all three
murine models. As expected, the total numbers of perturbed TFs in
murine cancer models is higher than that in PTEN inducible system.
Among the 20 PTEN-controlled TFs identified in the Pten MEF
system, all except Hlf are significantly altered in at least one of the
models. Egr1 has its activity altered solely in the Pten null murine
model. Eight TFAs (marked in bold in Figure 3A) exhibit concordant
alterations when the PTEN downstream AKT/mTOR pathway is
manipulated genetically or pharmacologically (Rapamycin treated
mAKT1 model). Interestingly, hi-c-Myc shares 13 TFAs changes with
Pten null or Pten null and mAKT1 models, of which seven are
concordantly regulated, including Ar, Creb1, Hoxc8, Elk1, Smad1,
Hif1a, Stat6 and c-Myc (Figure 3B). Since c-Myc transcription level
and activity is regulated by PTEN, these seven TFAs may reflect the
epistatic component of PTEN/AKT/mTOR and c-Myc. The
remaining 5 TFAs (* in Figure 3A and B) are discordantly regulated
by c-Myc and the PTEN/AKT/mTOR pathway, either due to non-
overlapping function and/or additional alterations accumulated in
vivo during tumor initiation and progression of these in vivo models.
In brief, the activities of the majority of PTEN-controlled TFs are
altered in the murine prostate cancer models in vivo, and the
variations among the models might be explained by different genetic
background and stage of tumor development.
Signature of PTEN-controlled TFs correlates with PTEN
status in human cancers
We hypothesized that the TFAs controlled by PTEN
expression should reflect PTEN functional status in human
cancers. To test the hypothesis, we examined if tumor subgroups
determined by TFA-based unsupervised clustering are enriched
for tumors with distinct PTEN status. For this, we focused on
prostate, breast and brain tumors because 1) PTEN deficiency
frequently occurs in these cancers [27,31,32], and 2) large gene
expression datasets are publically available [32,33,34]. Out of 19
PTEN-controlled TFs (AR is removed from our analysis to
prevent bias toward prostate), we were able to derive 16, 15 and
16 TFAs from human prostate, breast and brain tumor datasets,
respectively, based on the availability of their target gene
expression values in the datasets. For each cancer type, patient
samples were first classified by unsupervised clustering based on
the signature TFAs then annotated with their associated
pathological grades or PTEN status, determined by either
CGH analysis for PTEN copy number (CN) alterations in
prostate cancers [35] or immunohistochemistry (IHC) and
mRNA array for PTEN expression in breast cancers [32]. For
brain tumors, PTEN status was first predicted by TFAs-based
unsupervised clustering, and then confirmed by us in a majority
of the samples by IHC analysis.
Figure 2. PTEN re-expression downregulates activities of c-MYC and LEF1 in PTEN-inducible PC3 cells. (A) Immunoblot showing PTEN
expression levels under Doxycycline induction. (B) Bar graphs showing fold changes of c-MYC and LEF1 mRNA expression by qPCR analysis. (C and D)
Bar graphs showing the target gene expression of c-MYC and LEF1 by qPCR analysis, respectively. *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0031053.g002
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As shown in Figure 4A, PTEN-controlled TFAs separate 112
prostate samples into three distinct groups. Group 1 contains mostly
lymph node metastatic samples in which 69% (9/13) have deleted
PTEN based on CN; Group 2 has mostly primary cancer samples in
which 31% (11/35) have PTEN CN changes, whereas Group 3
consists of a majority of normal prostate cancer samples with only
4.7% (3/64) PTEN CN changes. Of note, the overall rates of PTEN
CN alterations found in this cohort fit well with the results from
integrated genomic profiling of a larger group of human prostate
cancer samples [27]. The heatmap of clustered TFA levels shows
that the activities of EGR1, ELK1, JUN, and NF-kB1 are
significantly (**, t-test p,0.001) higher in PTEN negative samples
while STAT6 activity is lower in PTEN negative samples, as
compared to those in the PTEN positive samples (Figure 4A).
PTEN-controlled TFA patterns can also be used as signatures to
separate PTEN negative from PTEN positive breast cancers
(Group 1 vs. Group 3 respectively in Figure 4B and S3A). The
same TFA-based analysis on Netherland Cancer Institute (NKI)
published breast cancer dataset that does not have associated
PTEN status [36], also classifies breast cancer in three subgroups,
and the Group 1, predicted to be PTEN negative, is associated
with poor differentiated, ER-negative basal-like phenotype [37]
(Figure S3B), which is consistent with our recent publication [38].
Similarly, PTEN-controlled TFAs can separate grade 4
glioblastomas from grade 3 gliomas (Group 1 vs. Group 2 in
Figure 4C and S3C). As expected, patients within the PTEN TFA-
positive group (Group 2) have mostly grade 3 tumors and longer
disease specific survival (DSS) while patients within the PTEN
TFA-negative group (Group 1) have more aggressive tumors and
shorter DSS. We then compared DSS of patients within Group 1
whose PTEN status were determined by IHC analysis (PTEN IHC
positive = blue bar, 17 patients; PTEN IHC negative = red bar, 16
patients) and found that PTEN IHC-positive patients have nearly
identical DSS as PTEN IHC-negative patients (log-rank test
Figure 3. PTEN-regulated TFAs are significantly increased in murine prostate cancer models in vivo. (A) Heatmap showing changes of
PTEN-regulated TFAs in PTEN inducible MEFs (PTEN null compared to PTEN re-expression or PTEN WT) and murine prostate cancer models (compared
to WT control mice; Rapa: Rapamycin treatment). TFAs regulated by PTEN/AKT/mTOR pathway are marked in bold. TFAs exhibit discordant regulation
between c-Myc and the PTEN/AKT/mTOR pathway are marked by *. The purple and green asterisks indicate Myc-activating and suppressing TFs
respectively. (B) Triangle diagram summarizing the TFAs regulated by PTEN, AKT/mTOR and/or c-MYC.
doi:10.1371/journal.pone.0031053.g003
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p= 0.8, Figure 5A). Thus, PTEN IHC status does not significantly
segregate patients in terms of the functional outcome of DSS,
while PTEN TFA status does. This analysis illustrates the
advantage of using TFA-based signatures in evaluating PTEN
functional status over traditional IHC-based analysis. Together,
these results reveal the power of our approach in predicting PTEN
status and its pathological association in human cancers in general.
Predicting PTEN status using murine and human cancer
deduced TFA signatures
In addition to the PTEN-controlled TFAs derived from the
inducible PtenDloxp/Dloxp MEFs, we identified another 19 TFs whose
activities are significantly perturbed in the Pten null prostate cancer
mouse model (Figure S2). These TFAs are not changed by
transient PTEN re-expression in the MEF cell line. Interestingly,
Figure 4. PTEN-controlled TFAs predict PTEN status in human cancers. Unsupervised clustering analysis, based on PTEN-controlled TFAs,
was used to classify human tumor samples. (A) In prostate cancer, group 1 is largely composed by samples with PTEN copy number changes (CN, red)
and lymph node metastases (LN met, pink); Group 2 are primary cancer samples (light blue) with normal PTEN karyotype (blue) that are separated
from most of normal prostate tissues (white). TFAs that are significantly altered between group 1 and group 3 are mark by **, p,0.001. The heatmap
was plotted based on relative changes to the respective average TFAs of normal samples. (B) In breast cancer, group 1 is mostly comprised of samples
with PTEN-negative status (red) identified by immunohistochemistry (IHC). The majority of the samples in group 3 have positive PTEN status (blue),
while group 2 includes both positive and negative PTEN samples. (C) In brain tumors, most samples in group 1 are associated with PTEN negative
status (red). The PTEN negative subgroup is also correlated with higher tumor grade (green for grade 3 and purple for 4, respectively).
doi:10.1371/journal.pone.0031053.g004
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16 out of these 19 TFAs are concordantly regulated in the mAKT1
and hi-c-Myc models and are also altered upon rapamycin
treatment of the mAKT1 model. Since these TFAs are not subject
to the control of PTEN re-expression and may reflect the common
pathological changes associated with these prostate cancer models,
we coined them ‘‘prostate cancer-related TFAs’’. We tested the
power of both the PTEN-controlled TFAs that were defined in the
Pten inducible MEF system, and the prostate cancer-related TFAs
in predicting PTEN status in human cancers. The prostate cancer-
related TFA signatures can be used to classify PTEN status in
human prostate cancers to a similar accuracy as the PTEN-
controlled TFAs, but they had less cross-tissue predictive power as
they failed to reach significance levels when applied to breast and
brain tumors (Figure 5B, blue bars).
Gene expression signatures, extracted from dysregulated genes
in PTEN deficient cancer samples, have been used to predict
PTEN status in human breast cancers [32]. We therefore,
compared gene expression signature-based predictions to inferred
TFA signature-based predictions of PTEN status in human cancer
samples. Applying our trimming NCA algorithm to the breast data
set annotated with PTEN IHC status, we identified 15 TFs whose
inferred TFAs were significantly altered (t-test p,0.0001) (Figure
S4). Among these six, HLF, JUN, c-MYC, EGR1, SMAD1, and
HIF1A, were also identified as PTEN-controlled TFs (Figure 1C),
and four, ESR2, MYB, RELA, and USF1, as prostate cancer-
related TFs (Figure S2). 246 signature genes predictive of PTEN
status had been previously reported in the breast cancer dataset
[32]. Among these, 103 and 123 genes, respectively, had their
expression values measured in the prostate and brain cancer
datasets. As shown in Figure 5B, although both gene expression-
based (green bars) and TFA-based (gold bars) breast PTEN IHC-
based signatures can be used to predict PTEN status by
unsupervised clustering approach in human breast cancers, they
failed to do so for prostate cancers and brain tumors. These results
demonstrate that the transcriptional network-inferred PTEN-
controlled TFAs are generally more reliable than expression-based
gene sets in representing PTEN functional status.
Specific sets of PTEN-controlled TFAs preferentially
contribute to different tumor development
Given that the PTEN-controlled TFA signatures are associated
with PTEN status in prostate, breast and brain tumors, we next
asked if a particular subset of the transcription factors play more
important role in each individual tumor type. To this end, we first
compared each TFA between PTEN positive and negative
samples, identified by both IHC/CN and TFA-based analysis.
Figure 6A shows the log10 transformed p-value of the t-test of such
comparisons in each tumor type. The first six TFAs, i.e., HLF,
ELK1, JUN, SMAD1, STAT6 and c-MYC, are significantly
(p,0.05) altered in the PTEN negative group in all three cancers.
STAT6 TFA is decreased while the others TFA are increased in
the PTEN negative group. The degree of overlap of the tumor
type-specific PTEN-controlled TFAs is summarized by a Venn
diagram in Figure 6B.
We further investigated the possible interactions among the
TFAs by examining pair wise correlation coefficients of inferred
TFAs across patient tumors in each tissue type. The absolute
correlation coefficients between the pairs are illustrated in
Figure 6C–E for human prostate, breast and brain tumors,
respectively. In general, the TFAs that more significantly track
with PTEN status are highly correlated with each other, and
assemble together into clusters that may reflect common upstream
signaling-based activation mechanisms. Notably, in each tumor
type, more than one TFA clusters are formed, suggesting that
PTEN regulates TFAs through more than a single signaling
pathway. The overlapping and specific TFA signatures in different
types of human cancers provide a transcription factor-based guide
to the mechanisms of cancer development caused by PTEN loss,
and offer TFA-based rationales for designing new therapeutic
regimen for treating PTEN null cancers and also monitoring PI3K
pathway targeted treatment responses.
Discussion
In this study we used NCA and its complementary trimming
algorithm to reveal 20 TFs that immediately respond to the
expression of PTEN in a PTEN inducible system. We found that
the PTEN immediate responsive gene-based TFA signatures are
more accurate and sensitive than either cancer-based TFA or gene
expression-based analyses in predicting PTEN functional status in
human cancers. These TFA-based signatures, therefore, provide
readout of transcription factor activity even if their mRNA levels
do not change, and help to overcome the complexity of
Figure 5. Enhanced robustness of TFA-based signatures in
predicting PTEN status in human cancer. (A) The Kaplan-Meier
survival curves of patients with brain tumors stratified according to
PTEN-controlled TFA and IHC analyses. (B) Log10 transformed p-values
of the x2 test evaluating the association of PTEN status with the
hierarchical clustering-determined groups of human tumors. Clustering
results are based on PTEN-controlled TFAs (red; Figure 3), prostate
cancer-related TFAs (blue), TFA-based (gold) and gene expression-
based (green) signatures derived from PTEN IHC data in breast tumors.
When three major clusters are observed in prostate and breast cancers,
the x2 tests are performed to associate different PTEN status in group 1
and groups 2 plus 3.
doi:10.1371/journal.pone.0031053.g005
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multifactorial post-transcriptional PTEN signaling pathway regu-
lations. Since mRNA profiles are currently measureable in clinical
settings, our TFA-based signatures provide new rationales for
stratifying patients according to their PTEN functional status and
for monitoring treatment outcome in PI3K-targeted therapies.
Our study testifies to the power of combining traditional genetic
and biochemical approaches with mathematic algorithms in
deciphering complicated transcription regulatory networks. NCA
complements other classical bioinformatics methods, such as
Principal Component Analysis (PCA) and Independent Component
Analysis (ICA). In contrast to PCA and ICA, NCA utilizes
biochemical constraints, i.e., the relationship between transcription
factors and their regulated genes, rather than statistical or
mathematical constraints in data deconvolution. This means if target
genes of a certain TF concordantly altered their expressions, even
though at the subtle levels upon stimulation, its NCA-derived TFA
will show significantly changes. Besides, NCA also detangles effects of
multiple TFs regulating a same gene. TFA profiles are more robust
and reliable in representing the real activities than the expression of a
TF specific target gene which may not be expressed in all tissues. This
explains why TFA-based signatures are more reliable than gene-
based signatures in predicting PTEN status in different tumor types.
NCA has been used to reveal biological relevant network structure
and regulatory dynamics in bacteria [17,39,40,41,42], Saccaramyces
Figure 6. Subsets of PTEN-controlled TFAs preferentially function in specific types of tumors. (A) t-test p-values comparing TFAs of the
subgroups based on PTEN status and clustering results as shown in Figure 5 in three tumor types. In the t-tests performed on of prostate and breast
cancers, PTEN positive samples in group 3 were used as the PTEN positive functional status, the PTEN negative samples in group 1 as the PTEN
negative functional status. Similarly, in brain tumor PTEN IHC positive samples in group 2 and PTEN IHC negative samples in group 1 were selected
for representing PTEN positive and negative functional status respectively. The red line highlighted the 6 TFAs significantly (p,0.05) altered between
tumor subgroups in three tumor types. (B) Venn diagram summarizing the overlap of the TFAs that contribute to the discrimination of tumor
subgroups with different PTEN status in different tumor types. (C–D) Heatmap of the absolute Pearson correlation coefficients between NCA-inferred
TF activity profiles across the tumor samples from prostate (C), breast (D) and brain (E) cancers, indicating groups of co-active transcription factors
may function together.
doi:10.1371/journal.pone.0031053.g006
PTEN Controlled Transcription Factor Activities
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31053
cerevisiae [41,43] and mouse [44]. In our study, the PTEN-controlled
TFA signatures deduced by our NCA analysis have been validated
experimentally and bioinformatically across in vitro cell lines, in vivo
animal models and in patient samples.
A shortcoming of NCA is that it depends on the information of
TF and target gene relationship. For instance, although FOXO
activity is known to be regulated by PTEN controlled PI3K/AKT
pathway, FOXO TFA cannot be derived in PTEN inducible
system because its target gene expression values are not available
in the database we used. Nevertheless, the results obtained from
our analyses are quite robust.
Although PTEN is not a TF, it can regulate TFAs through
either phosphatase-dependent or -independent mechanisms. In
the prostate cancer mouse models, the majority of TFs perturbed
in the Pten null mouse exhibit concordant alterations in their
activities when the PTEN downstream AKT/mTOR pathway is
manipulated genetically or pharmaceutically by the mTOR
inhibitor rapamycin. This result implies that PTEN controls TFAs
through its phosphatase activity by regulating the PI3K/AKT/
mTOR pathway, which is known for regulating activities of several
TFs including NF-kB [23], p53 [10], FOXO [9] and CREB [45].
These TFs may also serve as co-activators or repressors for other
TFs. Interestingly, we found c-MYC level and activity is directly
regulated by PTEN expression and a significant overlap between
hi-c-Myc and Pten null or mAKT1 prostate cancer models in their
associated prostate cancer-associated TFAs. It is worthy to note
that c-MYC target genes that are perturbed by PTEN expression
involve the regulation of cell growth, cell metabolism, and protein
synthesis [46,47,48,49], suggesting that the c-MYC-regulated
target genes may potentially play important roles in the
development of PTEN-deficient cancers. PTEN can also function
independent of its phosphatase activity to regulate cell migration
[50], p53 [10] and APC-CDH2 [51]. It is conceivable that PTEN
regulates a subset of TFAs, such as EGR1, LEF1, HLF, and
STAT6 (Figure 3), through its phosphatase-independent function-
al domains [6]. Whether PTEN needs to be located in the nuclear
to perform such a function requires further investigation.
Our study reveals common and cancer tissue type-specific
regulation of TFAs by the PTEN tumor suppressor. The six
common PTEN-controlled TFAs including c-MYC most likely
play an essential role in tumor development caused by PTEN loss
and their activity may serve as surrogate markers for determining
PTEN functional status and measuring response to targeted
therapy. Other tissue-type-specific regulated TFAs may help us
understand PTEN’s tissue-specific function. The PTEN-controlled
TFAs deduced by NCA, therefore, will aid in stratifying cancer
patients according to PTEN functional status and in deciphering
the complicated transcription regulatory networks controlled by
the PTEN tumor suppressor. Although targeting transcription
factors with small molecules remains challenging, recent works by
Bradner and colleagues on selective inhibitions of BET bromodo-
mains [52] and NOTCH transcription factor complex [53]
provide promising direction of this approach. Since efficient
targeting the intermediate effectors of the PTEN controlled
signaling pathway is difficult because of the feedback loops and
cross-talks among intracellular signaling pathways, our study may
guide the future efforts in targeting PTEN deficient cancers
through disrupting its regulated transcriptional architectures.
Materials and Methods
Cell culture and transfection
PTEN-inducible mouse PtenDloxp/Dloxp MEF cells [21] or PC3
[6,54] cells were cultured in DMEM or RPMI medium,
respectively, supplemented with 10% tetracycline-free fetal calf
serum (Invitrogen), 100 U/ml penicillin and streptomycin (Gibco).
Real-time PCR
Total RNAs were extracted using RNeasy Mini kit (Qiagen).
RNAs were reverse-transcribed by oligo(dT) primer using
Superscript RT-PCR kit (Invitrogen), according to the manufac-
turer instructions. PCR reaction was performed under the
following conditions: 94uC for 3 min; 94uC 30 Sec; 58uC for
30Sec; 72uC for 30 Sec for 40 cycles; and 72uC for 10 min, using
iQ SYBER Green Supermix Kit from Bio-Rad. Results were
analyzed by the relative quantification method and expressed as
relative RNA levels (DCT, difference of cycling threshold). DCT
values represent CT [gene]-CT [GAPDH], thus higher values
indicate relatively lower expression levels. Primer sequences used
for real-time PCR were retrieved from PrimerBank website.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitations were modified from the EZ-
ChIP (Upstate) protocol using antibodies: anti-c-Myc (A14, Santa
Cruz) anti-LEF1 (C-19, Santa Cruz). The percentage of the bound
DNA was quantified against the original DNA input using real
time PCR analysis (Biorad). Primer sequences used for ChIP are as
follows:
BCAT-59: AATCCGCTAGGTCGCGAGT; BCAT-39: AGCA-
AGACCTGGGGCAGT
CDK4-59: TTACACTCTTCGCCCTCCTC; CDK4-39: ATG-
TGACCAGCTGCCAAAG
EIF4E-59: CAGGGCCAAACGGACATA; EIF4E-39: CAATA-
CTCACCGGTTCGACA
SHMNT1-59: GCAGAGTGCACCTTCCTGA;
SHMNT1-39: GTGCCACCAGTCCCAGAC
WISP1-59: GGGATAGCAAGCATCCAGAG;
WISP1-39: CCTTCATGACACGTGAAAGC
DNA microarray data preprocessing
All the array datasets were downloaded from public domains,
and were MIAME compliant. Mouse and MEF expression data
was available through NCBI’s Gene Expression Omnibus (GEO)
with accession IDs GSE29010 and GSE1413, and normalized by
RMA method. Human expression data sets were downloaded
from GEO and other public domains (see Text S1). If a gene has
multiple probesets representing it, its expression was evaluated as
the average of its probesets.
Transcription factor activity (TFA) analysis
NCA is built based on log-linear model in which gene
expression ratios are log-linearly proportional to activity ratios of
their regulators. In the NCA pre-processing steps, expression data
sets from single channel Affymetrix arrays were set in log ratios
comparing the conditions of interest (e.g. Pten null, hi-Myc,
tumors) to the references (e.g. WT, normal). Biological repeat
arrays were averaged first before calculating the log ratios to filter
out extreme value of log-ratio.
We used the network structure information provided by
Transcriptional Regulatory Element Database (TRED) from Cold
Spring Harbor Laboratory [55], in which the connectivity
information is based on experimental validation and motif
searching. NCA and trimming algorithm [16] were used to
reconstruct the transcriptional network for each data set. In the
study, we only used the experimental-based TF-gene relationships
to minimize the false positive connection defined by motif
searching. The statistical significance of TFAs in murine datasets
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was justified based on random sampling network expression [16].
In brief, we first generate n,200 random networks whose gene
expression data is random sampled from whole genome. Such
random networks are then analyzed by NCA using the same
network structure as the interested one. The collection of TFAs
obtained from analyzing random networks form the null
distributions. For each original TFA in individual experiments,
the TFA modified z-score was calculated based on the median and
median of absolute deviation to determine how significantly the
TFA is perturbed under the experimental conditions. The median
and median of absolute deviation, instead of mean and standard
deviation, are used to avoid the effect of outliners.
Clustering analysis
Cluster 3.0 was used for the unsupervised hierarchical clustering
analysis using TFAs/gene expression. The similarity between
samples was represented by the cosine (or un-centered correlation)
metric. Complete linkage was used to clusters samples. In the
heatmap of prostate data the TFAs are colored code based on their
relative values to the respective averages of normal samples to
illustrate the direction of TFA variation to normal prostate tissue.
Pair wise correlation coefficient analysis
In each human cancer dataset, Pearson correlation coefficient
between each pair of TFAs was calculated. The unsupervised
hierarchical clustering analysis was then used to rearrange the
order of TFAs in the matrix of the absolute correlation coefficients.
Western blot analysis
Whole-cell extraction was described detail in [21]. Cell lysates
were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, transferred onto nitrocellulose (Bio-Rad), and
followed by Western blot analysis using PTEN (9552; Cell
Signaling), c-MYC (Santa Cruz), STAT6 (Santa Cruz), p-STAT6
(Abcam), JUN and p-JUN (Cell Signaling) antibodies. Quantifi-
cation was performed with BioRad Image Lab software.
Supporting Information
Figure S1 Validation of PTEN-inducible systems. (A)
Restoration of PTEN expression suppressing the expression of the
p90 isoform, but not p76 isoform of MDM2 in PTEN inducible
PC3 cells. (B) PTEN re-expression does not change the c-MYC,
STAT6 and c-JUN total protein levels but does alter the ratio of
phosphor-c-JUN to total c-JUN. Numbers indicate the relative
ratio of phosphorylated to total protein, or the levels of c-Myc
protein, with the PTEN null state defined as unity.
(TIFF)
Figure S2 Heatmap of TFAs changes deduced from gene
expression profiles in PTEN inducible MEFs and
prostate cancer mouse models. Heatmap showing PTEN-
controlled TFAs that are significantly altered in PTEN-inducible
MEF tissue culture cells; and a set of prostate cancer-related TFAs
that are significantly altered during tumorigenesis in murine
prostate cancer models, but not by re-expression of PTEN in the
PTEN-inducible MEF system (Rapa: Rapamycin treatment).
(TIF)
Figure S3 The PTEN-control TFA-based unsupervised
clustering analysis. Unsupervised clustering analysis, based on
PTEN-controlled TFAs, was used to classify human tumor
samples. (A) the first and (B) the second (NKI) breast cancer data
sets and in (C) brain cancer dataset. In the first breast tumor data
set (A), PTEN-controlled TFA-based unsupervised clustering
yields a clustering pattern of tumor PTEN negative status (Group
1). As for the second breast cancer data set the dendrogram also
illustrates the association of PTEN-negative Group 1 with poorly
differentiated, ER-negative and basal-like phenotype.
(TIF)
Figure S4 NCA-inferred TFAs significantly altered in
human breast cancer based on PTEN IHC. Log10-
transformed t-test p values for each TFA between samples of
different IHC-based PTEN status. The graph shows the 45 TFs
with the highest log10-transformed p-values. The p-values .0.1 of
the other 25 TFs are not shown. The dashed line (p = 1e-4)
indicates the threshold value for selecting the TFA-based PTEN-
IHC-derived signatures used in the analysis in Figure 5 (gold).
(TIF)
Table S1 List of PTEN immediately controlled genes in
MEFs.
(XLS)
Text S1 Supporting Information.
(DOC)
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